Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Astrocytoma 2Adenomatous Polyposis Coli 2Neoplasms 1Melanoma 1Glioma 1Glioblastoma 1Colonic Polyps 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

guselkumab 2Sulindac 2Eflornithine 2Celecoxib 2trifluridine tipiracil drug combination 1rofecoxib 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Endoscopy 1Eicosapentaenoic Acid 1Duration of Therapy 1Docosahexaenoic Acids 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Adenomatous Polyposis Coli × Eflornithine × Clear all
NCT01483144 2021-06-08

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Completed
171 enrolled 13 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT01245816 2015-04-24

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Withdrawn
Gastrointestinal

Colonic Polyps, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡